<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.advancesinsmallanimal.com/?rss=yes"><title>Advances in Small Animal Medicine &amp; Surgery</title><description>Advances in Small Animal Medicine &amp; Surgery RSS feed: Current Issue. Each month,  
 Advances in Small Animal Medicine and Surgery 
  features abstracts of material from recent publications and 
presentations, followed by comments from specialists in the field. Small animal veterinarians and veterinary technicians gain new insight 
into specific topics and increase their skills in judging how to apply new tests and treatments in practice situations.</description><link>http://www.advancesinsmallanimal.com/?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2010 Elsevier Inc. All rights reserved. </dc:rights><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:issn>1041-7826</prism:issn><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:publicationDate>August 2010</prism:publicationDate><prism:copyright> © 2010 Elsevier Inc. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS1041782610000988/abstract?rss=yes"/><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS104178261000099X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS1041782610001003/abstract?rss=yes"/><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS1041782610001015/abstract?rss=yes"/><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS1041782610001027/abstract?rss=yes"/><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS1041782610001039/abstract?rss=yes"/><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS1041782610001040/abstract?rss=yes"/><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS1041782610001052/abstract?rss=yes"/><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS1041782610001064/abstract?rss=yes"/><rdf:li rdf:resource="http://www.advancesinsmallanimal.com/article/PIIS1041782610001076/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS1041782610000988/abstract?rss=yes"><title>Is Dietary L-Lysine Effective for Treatment of Feline Ocular Disease Caused by Feline Herpesvirus-1?</title><link>http://www.advancesinsmallanimal.com/article/PIIS1041782610000988/abstract?rss=yes</link><description>Since the early 2000s, oral supplementation of L-lysine has been used to treat ocular disease in cats that was attributable to feline herpesvirus (FHV). Local (ocular) signs of disease that included conjunctivitis, blepharospasm, and ocular discharge were felt to improve when oral supplementation with a 250 or 500 mg bolus was administered once to twice daily.</description><dc:title>Is Dietary L-Lysine Effective for Treatment of Feline Ocular Disease Caused by Feline Herpesvirus-1?</dc:title><dc:creator>Paul A. Gerding</dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Guest Editorial</prism:section><prism:startingPage>1</prism:startingPage><prism:endingPage>2</prism:endingPage></item><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS104178261000099X/abstract?rss=yes"><title>Dietary Factors and Pancreatitis</title><link>http://www.advancesinsmallanimal.com/article/PIIS104178261000099X/abstract?rss=yes</link><description>High-fat diets can induce pancreatitis and increase its severity in dogs. The role of other dietary factors in the development of pancreatitis in dogs has not been evaluated.   To estimate associations between dietary factors and pancreatitis in dogs.</description><dc:title>Dietary Factors and Pancreatitis</dc:title><dc:creator></dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Clinical Pathology</prism:section><prism:startingPage>2</prism:startingPage><prism:endingPage>3</prism:endingPage></item><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS1041782610001003/abstract?rss=yes"><title>Permethrin Spot-On Intoxication of Cats</title><link>http://www.advancesinsmallanimal.com/article/PIIS1041782610001003/abstract?rss=yes</link><description>Permethrin is the most common cause of poisoning in pet cats. The duration of required treatment ranges from days to weeks. In a recent retrospective study, the average duration of hospitalized treatment was 24 to 48 hours. However, 45% of cases required continuing treatment after discharge from the hospital.</description><dc:title>Permethrin Spot-On Intoxication of Cats</dc:title><dc:creator></dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Dermatology</prism:section><prism:startingPage>3</prism:startingPage><prism:endingPage>3</prism:endingPage></item><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS1041782610001015/abstract?rss=yes"><title>Permethrin Toxicity in Cats</title><link>http://www.advancesinsmallanimal.com/article/PIIS1041782610001015/abstract?rss=yes</link><description>Permethrin is a class I pyrethroid insecticide which has low toxicity in most mammalian species and is commonly used in spot-on pesticide preparations manufactured for flea control of dogs. Pyrethrins and pyrethroids are fat-soluble compounds that in most mammals can rapidly metabolize and excrete. However, cats appear highly sensitive to the effects of permethrin, possibly due to the deficiency of hepatic glucuronosyltransferase.</description><dc:title>Permethrin Toxicity in Cats</dc:title><dc:creator></dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Dermatology</prism:section><prism:startingPage>3</prism:startingPage><prism:endingPage>4</prism:endingPage></item><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS1041782610001027/abstract?rss=yes"><title>Optimal Testing of Thyroid Hormone Concentrations After Methimazole Treatment</title><link>http://www.advancesinsmallanimal.com/article/PIIS1041782610001027/abstract?rss=yes</link><description>The treatment of hyperthyroidism in cats includes pharmacologic management with methimazole and/or curative procedures, such as radioactive iodine therapy with I131, surgical thyroidectomy, and ablation of the thyroid gland with ethanol. Methimazole blocks thyroid hormone synthesis by inhibiting thyroid peroxidase. The optimal sampling time for therapeutic monitoring of thyroid hormones in cats has not been determined. Variation in duration and magnitude of suppression of thyroid hormones immediately after methimazole treatment has not been reported in hyperthyroid cats.</description><dc:title>Optimal Testing of Thyroid Hormone Concentrations After Methimazole Treatment</dc:title><dc:creator></dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Endocrinology</prism:section><prism:startingPage>4</prism:startingPage><prism:endingPage>4</prism:endingPage></item><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS1041782610001039/abstract?rss=yes"><title>Recombinant Human Thyrotropin Stimulation Testing in Cats</title><link>http://www.advancesinsmallanimal.com/article/PIIS1041782610001039/abstract?rss=yes</link><description>Radioiodine is the treatment of choice for feline hyperthyroidism. However, 6 to 30% of treated cases develop iatrogenic hypothyroidism, and up to 39% of treated cats have signs of chronic kidney disease (CKD) relapse after treatment of hyperthyroidism.</description><dc:title>Recombinant Human Thyrotropin Stimulation Testing in Cats</dc:title><dc:creator></dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Endocrinology</prism:section><prism:startingPage>4</prism:startingPage><prism:endingPage>5</prism:endingPage></item><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS1041782610001040/abstract?rss=yes"><title>Safety and Efficacy of Laser Lithotripsy in Dogs</title><link>http://www.advancesinsmallanimal.com/article/PIIS1041782610001040/abstract?rss=yes</link><description>In 1986, ureteroliths were first removed in humans by use of a 504-nm pulsed dye laser. Since then, laser lithotripsy has been reported to effectively eliminate uroliths in humans, horses, goats, and pigs. In 2003, in vitro studies revealed that the Ho:YAG laser consistently shattered canine uroliths of all types into extractable fragments (less than 3.5 mm in diameter) in less than 30 seconds. When laser lithotripsy was performed in dogs with naturally occurring urolithiasis, urolith fragmentation was effective, but it required more than 1 to 1.5 hours to complete the urolith removal.</description><dc:title>Safety and Efficacy of Laser Lithotripsy in Dogs</dc:title><dc:creator></dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Nephrology/Urology</prism:section><prism:startingPage>5</prism:startingPage><prism:endingPage>6</prism:endingPage></item><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS1041782610001052/abstract?rss=yes"><title>Canine Multicentric Lymphoma Treatments</title><link>http://www.advancesinsmallanimal.com/article/PIIS1041782610001052/abstract?rss=yes</link><description>Multidrug chemotherapy protocols are the standard treatment for canine lymphoma. Changes in the standard drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone), their dose scheduling, or both has failed to result in significant improvement in 1st remission rate (70 to 88%) or 1st remission duration (168 to 270 days).</description><dc:title>Canine Multicentric Lymphoma Treatments</dc:title><dc:creator></dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Oncology</prism:section><prism:startingPage>6</prism:startingPage><prism:endingPage>6</prism:endingPage></item><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS1041782610001064/abstract?rss=yes"><title>Tyrosine Kinase Inhibitor Effects on Canine Mast Cell Tumors</title><link>http://www.advancesinsmallanimal.com/article/PIIS1041782610001064/abstract?rss=yes</link><description>Mast cell tumors (MCT) are the second most common malignant tumors in dogs. Most originate in the skin or subcutaneous tissues, but they can occur as primary tumors in the intestines, liver, or spleen. Canine MCTs possess a wide range of biological behaviors, from benign to extremely aggressive, leading to metastasis and eventual death. Histologic grading using the Patnaik system (grade 1- low; 2 - immediate; 3 - high) has proven to be the most reliable prognostic indicator.</description><dc:title>Tyrosine Kinase Inhibitor Effects on Canine Mast Cell Tumors</dc:title><dc:creator></dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Oncology</prism:section><prism:startingPage>6</prism:startingPage><prism:endingPage>8</prism:endingPage></item><item rdf:about="http://www.advancesinsmallanimal.com/article/PIIS1041782610001076/abstract?rss=yes"><title>Spread of Canine Herpesvirus-1 Infection</title><link>http://www.advancesinsmallanimal.com/article/PIIS1041782610001076/abstract?rss=yes</link><description>The clinical manifestations and disease severity of canine herpesvirus-1 (CHV-1) depend on the dog's age when first infected. Fetal and neonatal primary CHV-1 infection results in severe disseminated disease that is often fatal, characterized by multi-organ hemorrhagic necrosis and meningoencephalitis. Primary CHV-1 infection in older dogs is frequently subclinical or results in localized respiratory tract, genital, or mucosal disease. Ocular lesions caused by CHV-1 infection in mature dogs include conjunctivitis and dendritic ulcerative keratitis.</description><dc:title>Spread of Canine Herpesvirus-1 Infection</dc:title><dc:creator></dc:creator><dc:identifier></dc:identifier><dc:source>Advances in Small Animal Medicine &amp; Surgery 23, 8 (2010)</dc:source><dc:date>2010-08-01</dc:date><prism:publicationName>Advances in Small Animal Medicine &amp; Surgery</prism:publicationName><prism:publicationDate>2010-08-01</prism:publicationDate><prism:volume>23</prism:volume><prism:number>8</prism:number><prism:issueIdentifier>S1041-7826(10)X0008-1</prism:issueIdentifier><prism:section>Ophthalmology</prism:section><prism:startingPage>8</prism:startingPage><prism:endingPage>8</prism:endingPage></item></rdf:RDF>